Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

NCT02890173 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT02890173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2016
Completion date
July 11, 2017
Enrollment
1,001 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension